Checkpoint inhibitors have replaced docetaxel as the new standard second-line therapy in advanced non-small cell lung carcinoma (NSCLC), but little is known about the potential predictive value of clinical and molecular characteristics.
A dvanced non-small cell lung carcinoma (NSCLC) is an incurable disease that is associated with a poor prognosis. Globally, it is the leading cause of cancer-related death.
1 Docetaxel has been the standard of care for advanced NSCLC following disease progression with platinum doublet chemotherapy. 2,3 However, docetaxel is associated with only modest efficacy but substantial toxicity. With the recent advancement in immune checkpoint inhibitor therapies 4-8 that target the PD-L1 (programmed cell death 1 ligand 1) and PD-1 (programmed cell death 1) pathways, these agents have recently replaced docetaxel as the new standard second or later line of treatment.
Identifying clinical or molecular factors that predict benefit of checkpoint inhibitors in advanced NSCLC remains crucial for the selection of appropriate patients for this class of therapy. The PD-L1 expression on tumor cells is regarded as the best available biomarker to predict the efficacy of checkpoint inhibitors in NSCLC and other tumors. 9 Although there is a linear relationship between the size of the benefit of checkpoint inhibitors and the level of tumor PD-L1 expression in NSCLC, 4, 5, 7, 8, 10 tumor responses have still been observed in those with low or undetectable PD-L1 expression. Furthermore, among the 4 PD-1 and PD-L1 inhibitors in clinical development or approved for routine use in NSCLC, unique assays have been used as "companion diagnostics" for determining tumor PD-L1 expression. 11 The thresholds used to determine PD-L1 positivity for the different PD-1 and PD-L1 inhibitors have been defined differently. The limited predictive value of this test, together with the lack of harmonization between assays, represents a major limitation to the routine clinical use of PD-L1 assay. However, efforts are under way to address these issues. Specifically, the Blueprint PD-L1 immunohistochemistry assay comparison project 11 has reported similar analytic performances for 3 (22C3, 28-8, and SP263) of the 4 assays examined, suggesting that these assays could be used interchangeably.
In this meta-analysis, we examined the potential predictive value of routinely collected data on patient, disease, and molecular characteristics to guide the selection of patients with advanced NSCLC for checkpoint inhibitors in second and later lines of therapy. Because individual randomized clinical trials were not designed nor adequately powered to demonstrate a treatment difference between subgroups of patients on the basis of their clinical or tumor characteristics, a meta-analysis of trials comparing an immune checkpoint inhibitor with chemotherapy, with overall survival (OS) as the main end point, will help address this clinically important need.
Methods

Study Eligibility and Identification
Eligible randomized controlled trials that compared checkpoint inhibitors with docetaxel in the second-line setting were identified from MEDLINE, Embase, PubMed, and the Cochrane Central Register of Controlled Trials. We included articles published in the English language between January 1, 1996, and January 30, 2017, using the following terms: advanced or metastatic lung neoplasm, cancer, or carcinoma; checkpoint inhibitor; PD-1; PD-L1; ipilimumab; nivolumab; pembrolizumab; atezolizumab; and randomized controlled clinical trial. To identify unpublished studies, we searched abstracts from conference proceedings of the American Society of Clinical Oncology, the European Society for Medical Oncology, and the World Conference on Lung Cancer.
Data Extraction
For each included trial, we extracted the trial name, year of publication or conference presentation, patients' clinicopathological characteristics, type of chemotherapy, and type of checkpoint inhibitor. We also retrieved the hazard ratio (HR) and 95% CI for OS of the intention-to-treat population and the following predefined subgroups: epidermal growth factor receptor (EGFR) status (mutation vs wild type), Kirsten RAS (KRAS) status (mutation vs wild type), smoking status (never smokers vs ever [current or former] smokers), age (<65 years vs ≥65 years), sex (female vs male), performance status (PS; 0 vs 1), tumor histology (squamous vs nonsquamous), and central nervous system metastasis (present vs absent). Two of our authors (C. K. L. and J. M.) extracted data independently, and we resolved the discrepancies by consensus.
Statistical Analysis
We used the fixed-effects inverse-variance-weighted method to pool results to estimate the size of the treatment benefit. Tests of interaction were used to assess the differences in treatment effect across these subgroups.
We performed a sensitivity analysis by excluding trials of PD-L1 inhibitors (atezolizumab), recognizing that it may have a different efficacy from PD-1 inhibitors (nivolumab and pembrolizumab). Publication bias was evaluated by examining the funnel plot of the effect size for each trial against the reciprocal of its SE.
We used the χ 2 Cochran Q test to detect any heterogeneity across the different trials and between subgroups. The nominal level of significance was set at 5%. All 95% CIs were 2-sided.
Results
The search strategy identified 5 eligible trials ( Figure 1) . The . Treatment with a checkpoint inhibitor compared with chemotherapy was statistically significantly associated with a 31% reduction in the risk of death (HR, 0.69; 95% CI, 0.63-0.75; P < .001) in the intention-to-treat population.
There was no significant heterogeneity in the overall treatment effect across the 5 trials (χ 2 = 3.11; P = .68).
Subgroup Analyses by EGFR and KRAS Mutation Status
Treatment effect was evaluable for 2261 patients (74.7%), with data available on EGFR status from 4 trials. 4,6-8, 12 A total of 764 patients (25.3%) for whom the EGFR status was not known were excluded from analysis. In the EGFR wild-type subgroup (1990 [88.0%]), the pooled HR was 0.67 (95% CI, 0.60-0.75; P < .001; heterogeneity, P = .98). In the EGFR mutant subgroup (271 [12.0%]), the pooled HR was 1.11 (95% CI, 0.80-1.53; P = .54; heterogeneity, P = .88). There was a statistically significant treatment-EGFR mutation interaction (P = .005) ( Figure 2A ). Treatment effect was evaluable for 519 patients (17.2%), with data available on KRAS status from 3 trials. 4, 7, 8, 12 In the KRAS wild-type subgroup (371 [71.5%]), the pooled HR was 0.86 (95% CI, 0.67-1.11; P = .24; heterogeneity, P = .62). In the KRAS mutant subgroup (148 [28.5%]), the pooled HR was 0.65 (95% CI, 0.44-0.97; P = .03; heterogeneity, P = .62). There was no significant treatment-KRAS mutation interaction (P = .24) ( Figure 2B ).
Subgroup Analyses by Patient and Disease Factors
None of the patient factors predicted OS benefit with checkpoint inhibitors compared with docetaxel. Treatment effect was evaluable for 1963 patients (64.9%), and data were available on self-reported smoking status from 4 trials. 4, 5, 7, 8, 12 In the ever (current or former) smoker subgroup (1633 [83.2%]), the pooled HR was 0.69 (95% CI, 0.62-0.78; P < .001; heterogeneity, P = .66). In the never smoker subgroup (330 [16.8%]), the pooled HR was 0.79 (95% CI, 0.60-1.05; P = .07; heterogeneity, P = .36). There was no significant treatment-smoking interaction (P = .40) (eFigure 1A in the Supplement). Age (<65 years HR, 0.71 vs ≥65 years HR, 0.69; interaction, P = .85) (eFigure 1B in the Supplement), PS (0 HR, 0.69 vs 1 HR, 0.68; interaction, P = .74) (eFigure 1A in the Supplement), and sex (female HR, 0.70 vs male HR, 0.69; interaction, P =. 8 2 ) (eFigure 2 in the Supplement) did not predict OS benefit from checkpoint inhibitors. None of the disease factors examined predicted OS benefit from checkpoint inhibitors over docetaxel. The NSCLC tumors were classified histologically as squamous or nonsquamous, with treatment effect evaluable for 2921 patients (96.6%) from all included trials. In the squamous subgroup (813 [27.8%]), the pooled HR was 0.67 (95% CI, 0.57-0.80; P < .001; heterogeneity, P = .73). In the nonsquamous subgroup (2108 [72.2%]), the pooled HR was 0.70 (95% CI, 0.62-0.78; P < .001; heterogeneity, P = .78). There was no significant treatmenthistology interaction (P = .71) (eFigure 2C in the Supplement). The treatment effect was evaluable for 1687 patients (55.8%), with data on central nervous system (CNS) metastasis reported in 3 trials. 4 
Sensitivity Analysis
When the trials of PD-L1 inhibitors 7,8 were excluded, the overall treatment effect was similar (eFigure 3A in the Supplement). Subgroup analyses according to KRAS status, smoking status, and CNS metastasis were not possible because of an insufficient number of PD-1 trials that report these results. We observed a consistent result for the EGFR wild-type vs mutant subgroups (HR, 1.05 vs 0.66; interaction, P = .04) (eFigure3BintheSupplement) and for other subgroups (eFigure 3C and eFigure 4 in the Supplement).
Publication Bias
A funnel plot of the effect size for each trial against the precision showed no asymmetry (data not shown).
Discussion
This meta-analysis demonstrates that checkpoint inhibitors are statistically significantly associated with a 31% reduction in the risk of death compared with docetaxel in second and later lines of therapy for advanced NSCLC. Although there was an OS advantage for patients with EGFR wild-type tumors (pooled HR, 0.67; P < .001), there was no OS advantage seen for those with EGFR mutant tumors, and there was a nonsignificant trend toward worsened OS compared with docetaxel (pooled HR, 1.11; P =.54;EGFR status-treatment interaction, P = .005). In addition, there was a greater benefit in KRAS mutant subgroups, with a 35% reduction in the risk of death. Our findings confirm that EGFR mutation status can be used to predict checkpoint inhibitor benefits, with no OS advantage observed for EGFR mutant tumors and with a statistically significant interaction between EGFR status and treatment effect (EGFR mutant HR, 0.67 vs EGFR wild-type HR, 1.11; P = .005). In the absence of a statistically significant interaction between KRAS status and treatment effect (KRAS mutant HR, 0.86 vs KRAS wild-type HR, 0.65; P = .24), this meta-analysis does not provide sufficient evidence to recommend KRAS as a predictive biomarker for the selection of patients for checkpoint inhibitor therapy. This meta-analysis also confirms that age, sex, and PS 0 or 1 were not predictive of OS benefit with checkpoint inhibitors. However, this analysis does not allow an evaluation of the effect of these agents on patients with PS 2, who represent a large proportion of patients in routine clinical practice but were excluded from all recently conducted trials.
Our findings are consistent with those of previous studies 13, 14 that have reported the benefit of checkpoint inhibitor monotherapy, if any, are modest in tumors harboring EGFR mutations. Despite the high expression of PD-L1 in EGFR mutant tumors, 15, 16 we have previously hypothesized that the low mutational load 17, 18 associated with these tumors, as compared with other types of NSCLC, might provide a biological explanation for our findings. Other recent insights that may help to further elucidate the mechanisms of resistance include the finding that EGFR mutant tumors are associated with a high frequency of inactive tumor-infiltrating lymphocytes even though lymphocytes are present in the tumor microenvironment. 19 The finding that high CD73 expression on NSCLC and other tumors is associated with low PD-L1 expression and low densities of CD8 + tumor-infiltrating lymphocytes 20 may also provide an explanation given that EGFR activation is thought to induce CD73 expression. One hypothesis raised is that in the EGFR mutant tumors with overexpression of CD73, which is also associated with reduced expression of interferon gamma messenger RNA signature,
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CD73 results in immunosuppression via decreased T-cell activation and effector function and hence reduced benefit from checkpoint inhibitor therapies. Multiple factors could potentially account for our finding that checkpoint inhibitors had a greater therapeutic benefit for KRAS mutant than for KRAS wild-type NSCLC. Unlike EGFR mutant tumors, tumor-infiltrating lymphocytes are frequently present in the microenvironment of KRAS mutant tumors and are almost always active. 19 Mutations in STK11 or LKB1 and TP53 tumor suppressor genes commonly co-occur in KRAS mutant NSCLC. 22 Loss of TP53 function is associated with an increase in expression of PD-L1 23 and an increase in mutation burden. 18, 24 A recent study of 165 patients with KRAS mutant NSCLC who received PD-1 or PD-L1 therapy demonstrated that TP53 comutations are associated with a high likelihood of response, but mutational inactivation of STK11 or LKB1 is associated with de novo resistance. 25 30 and thereby greater benefit from checkpoint inhibitors. Reasons for these conflicting findings include the uncontrolled design and small sample size of previous studies, the possibility that the tumor response rate does not translate to OS improvement, the unknown consequence of crossover at disease progression, and the possibility that a molecular smoking signature but not selfreported smoking status correlates with treatment efficacy. 17 In our study, we were unable to ascertain how smoking status was defined in the different trials. The duration and quantity of tobacco exposure used to distinguish among never smokers, former smokers, and current smokers may therefore have differed across trials. Nevertheless, our results do not support the use of self-reporting smoking status in patient selection for checkpoint inhibitor therapy. With data available on more than half of the included patients, our study also demonstrates that the presence or absence of CNS metastases did not alter the OS benefit of checkpoint inhibitors (HR, 0.76 vs 0.71; treatment-CNS metastasis interaction, P = .71). Although these results are generalizable only to patients with good PS and who met the trial eligibility criteria, they are nevertheless encouraging. A previous phase 2 trial of patients with advanced cancer and untreated brain metastasis that reported a response rate of 33% in the NSCLC cohort 31 supports the result of our meta-analysis. As the PD-1 or PD-L1 inhibitors do not cross the blood-brain barrier, the ability of these agents to mobilize activated T cells into the CNS to control brain metastases represents a major therapeutic advance in the treatment of advanced NSCLC. With only a limited number of patients with known CNS metastasis in the included trials, future research is still required, including evalu-ation of the differences in efficacy of PD-1 vs PD-L1 inhibitor for patients with CNS metastasis. Our results have several important clinical and research implications. They might be useful for the selection of patients for checkpoint inhibitor therapy and would enhance drug development and the design and interpretation of future clinical trials. For patients with EGFR mutant NSCLC, our findings suggest immunotherapy should be considered only after exhaustion of other effective therapeutic options, such as EGFR tyrosine kinase inhibitors and chemotherapy. With differences in OS benefits for various subgroups, this metaanalysis will be important for economic analyses where the costs required to achieve these benefits will vary.
Strengths and Limitations
This meta-analysis has several strengths. We performed a comprehensive review using the most up-to-date trial data. We also overcame the problem of inadequate power of individual trials, allowing us to examine clinically important subgroup comparisons. The major limitation of this study is that EGFR and KRAS mutations were not determined universally by centralized testing, with EGFR not assessed in 764 patients (25.3%) and KRAS status not assessed in 2506 patients (82.8%), and where the different types of mutations were also unknown. In addition, the results were generalizable only to patient groups eligible for these trials. Importantly, we were unable to examine the effect of these agents in patients with poor PS, who represent a large proportion in routine clinical practice. Despite these limitations, to our knowledge this meta-analysis remains the largest study so far that incorporates results from 5 trials with more than 3000 patients.
Conclusions
Checkpoint inhibitors, compared with docetaxel, significantly prolonged OS in second and later lines of treatment for advanced NSCLC. Our findings of no OS benefit for EGFR mutant tumors suggest that checkpoint inhibitors should be considered only for this group after exhaustion of other effective therapies. In the absence of a statistically significant interaction between KRAS status and treatment effect, we cannot recommend KRAS as a predictive biomarker and larger studies are warranted to further investigate its predictive value. The findings of this meta-analysis could also assist in the design and interpretation of future trials and in economic analyses.
